Results 31 to 40 of about 178,392 (266)

Structural insights and therapeutic targets in Acinetobacter baumannii capsule biosynthesis

FEBS Letters, EarlyView.
Hypervirulent KL49 A. baumannii's capsular polysaccharide contains the nonulosonic acid 8‐epi‐Leg5,7Ac2, synthesized by epimerization via ElaA, ElaB, and ElaC. Crystal structures of ElaA, ElaB, and ElaC reveal their role in CMP‐Leg5,7Ac2 synthesis and regioselective C8 epimerization.
Woo Cheol Lee, Junho Jeong, Chae Yeong Lee, Hyunjoon Cho, Man Hwan Oh, Je Chul Lee, Jee‐Young Lee, Yangmee Kim   +7 more
wiley   +1 more source

Comparing methods to improve cone-beam computed tomography for dose calculations in adaptive proton therapy

Physics and Imaging in Radiation Oncology
Background and purpose: Proton therapy requires dose monitoring, often performed based on repeated computed tomography (reCT) scans. However, reCT scans may not accurately reflect the internal anatomy and patient positioning during treatment.
Casper Dueholm Vestergaard, Nadine Vatterodt, Ulrik Vindelev Elstrøm, Kenneth Jensen, Ole Nørrevang, Ludvig Paul Muren, Stine Sofia Korreman, Vicki Trier Taasti   +7 more
doaj   +1 more source

Beam and spin dynamics in the fast ramping storage ring ELSA: Concepts and measures to increase beam energy, current and polarization

EPJ Web of Conferences, 2017
The electron accelerator facility ELSA has been operated for almost 30 years serving nuclear physics experiments investigating the sub-nuclear structure of matter.
Hillert Wolfgang, Balling Andreas, Boldt Oliver, Dieckmann Andreas, Eberhardt Maren, Frommberger Frank, Heiliger Dominik, Heurich Nikolas, Koop Rebecca, Klarner Fabian, Preisner Oliver, Proft Dennis, Pusch Thorsten, Roth André, Sauerland Dennis, Schedler Manuel, Schmidt Jan Felix, Switka Michael, Thiry Jens-Peter, Wittschen Jürgen, Zander Sven   +20 more
doaj   +1 more source

Risk of second primary cancer from proton arc therapy of pediatric brain tumors

Physics and Imaging in Radiation Oncology, 2023
Proton arc therapy (PAT) is currently explored for clinical implementation, despite its associated low-dose bath. This study therefore aimed at evaluating the risk of radiation-induced second primary cancer (SPC) for PAT in pediatric brain tumor patients.
Laura Toussaint, Daniel J Indelicato, Ludvig P Muren, Camilla H Stokkevåg   +3 more
doaj   +1 more source

Structure‐forward targeting of claudins with synthetic binders

FEBS Letters, EarlyView.
Claudins form the paracellular barriers between epithelial and endothelial tissues at tight junctions and are targets for molecular binders with the goal of modulating barrier permeability. Claudin‐binding molecules are relevant in drug delivery or in altering claudin interactions with disease‐causing proteins.
Alex J. Vecchio
wiley   +1 more source

Three-year insights from a proton therapy centre: Evolving strategies in ependymoma treatment planning

Technical Innovations & Patient Support in Radiation Oncology
Background: Treatment of posterior fossa ependymoma with proton therapy (PT) is challenging due to the proximity to the brainstem and potential risk of brainstem toxicity.
Lieselotte Lauwens, Anneleen Goedgebeur, Tom Boterberg, Tom Depuydt, Dario Di Perri, Lorraine Donnay, Benjamin Ledoux, Kenneth Poels, Susana Santos Lopes, Karen Van Beek, Robin De Roover, Maarten Lambrecht   +11 more
doaj   +1 more source

Prospecting the protein design landscape

FEBS Letters, EarlyView.
This review outlines the current state of various protein design approaches. We discuss the current possibilities enabled by recently released tools, highlight future avenues to pursue in protein design, and underscore the crucial role of key databases and resources for successful protein design workflows.
Jakob R. Riccabona, Katharina T. Stonig, Jens Meiler, Clara T. Schoeder, Monica L. Fernández‐Quintero   +4 more
wiley   +1 more source

Leucine‐rich glioma inactivated 1 (LGI1) is a ganglioside‐binding protein

FEBS Letters, EarlyView.
Neuronal hyperexcitability associated with a decrease/absence of the extracellular protein LGI1 has been suggested to be primarily due to the downregulation of Kv1 channel expression. The molecular mechanisms underlying this decrease have not yet been elucidated.
Kévin Debreux, Christian Lévêque, Fodil Azzaz, Marion Sangiardi, Sarosh R Irani, Michael Seagar, Jacques Fantini, Oussama El Far   +7 more
wiley   +1 more source

Efficacy and Feasibility of Proton Beam Therapy in Relapsed High-Risk Neuroblastoma-Experiences from the Prospective KiProReg Registry

Current Oncology, 2022
Background: Despite an intensive multimodal treatment approach, approximately 50% of high-risk (HR) neuroblastoma (NB) patients experience progression. Despite the advances in targeted therapy, high-dose chemotherapy, and other systemic treatment options,
Danny Jazmati, Barbara Hero, Theresa M. Thole.-Kliesch, Julien Merta, Hedwig E. Deubzer, Christian Bäumer, Feline Heinzelmann, Stefanie Schulze Schleithoff, Friederike Koerber, Angelika Eggert, Rudolf Schwarz, Thorsten Simon, Beate Timmermann   +12 more
doaj   +1 more source

A context‐dependent modulatory role for eIF6 in acquired resistance to vemurafenib in melanoma

FEBS Letters, EarlyView.
Acquired resistance to vemurafenib upregulates the translation factor eIF6 in melanoma cells. Silencing eIF6 in resistant cells reduces proliferation and partially restores drug sensitivity, whereas its overexpression increases sensitivity across melanoma lines regardless of BRAF status, via modulation of mTOR, S6K, and MAPK signaling.
George Kyriakopoulos, Antonia Petropoulou, Alexandra Anastogianni, Angelina Bania, Vassilis Stamatakis, Argyris Alexiou, Chi‐Ping Day, Glenn Merlino, Katerina Grafanaki, Constantinos Stathopoulos   +9 more
wiley   +1 more source